HisMoDetect
Financiado
An Antibody Microarray for Histone Modifications
Histones are the major structural proteins of eukaryotic DNA. Two copies each of the core histones, H2A, H2B, H3 and H4, form the core nucleosome, the basic unit of chromatin. Histone tails protrude from the nucleosome structure a...
Histones are the major structural proteins of eukaryotic DNA. Two copies each of the core histones, H2A, H2B, H3 and H4, form the core nucleosome, the basic unit of chromatin. Histone tails protrude from the nucleosome structure and are subject to a variety of post-translational modifications on multiple residues, including methylation, acetylation, phosphorylation, sumoylation, ubiquitination and polyribosylation. These histone modifications dictate local and global structure of chromatin, rendering it active and decondensed (‘euchromatic’) or suppressed and compact (‘heterochromatic’) by the recruitment of chromatin-binding proteins that recognize and associate with specific modifications. Histone modifications are therefore the basic regulatory unit of gene expression, genomic silencing, developmental programs, cell division and essentially all cellular processes. Understanding this so-called ‘epigenetic’ landscape is therefore vital for all biological mechanisms. Currently a Western blot is required in order to determine the state of each of the dozens of different histone modifications. Because of the growing number of histone modifications, this procedure is time consuming and labour intensive. Here I suggest to develop an antibody microarray to monitor the levels of all histone modifications simultaneously. This method will be essentially useful for any tissue or cell type in any biological process, for diagnosis, prognosis and drug screening. In addition to basic research, our platform will enable fast and reliable screening for epigenetic effects of existing and novel drugs. We believe that such a product could serve many drug companies interested in direct and indirect effects of epigenetic and non-epigentic drugs.
ver más
Duración del proyecto: 20 meses
Fecha Inicio: 2015-07-30
Fecha Fin: 2017-03-31
Fecha Fin: 2017-03-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2017-03-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-PoC-2015:
ERC Proof of Concept Grant
Cerrada
hace 9 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
THE HEBREW UNIVERSITY OF JERUSALEM
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.76M€ |
Participante